ENDPOINTS NEWS1h
Tang Cap­i­tal’s Con­cen­tra bids for Sin­gu­lar Ge­nomics days af­ter Deer­field of­fer
A sec­ond buy­er has made an of­fer to buy the DNA se­quenc­ing com­pa­ny Sin­gu­lar Ge­nomics Sys­tems, po­ten­tial­ly ...
ENDPOINTS NEWS9h
FDA ap­proves As­traZeneca’s asth­ma med­ica­tion Fasen­ra to treat rare au­toim­mune con­di­tion
A few months after a key label expansion, AstraZeneca’s asthma treatment Fasenra has received FDA approval to treat a rare ...
ENDPOINTS NEWS13h
Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B
Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...
ENDPOINTS NEWS11h
Keytru­da adds new FDA ap­proval for a rare form of mesothe­lioma
Keytruda is already approved in more than 40 different oncology indications, but its latest label expansion is a first for ...
ENDPOINTS NEWS12h
No­vo Nordisk signs ge­net­ic med­i­cine pact, ink­ing deal with NanoVa­tion
Novo Nordisk is doubling down on its investment in genetic medicine-based biotechs, inking a new collaboration with a lipid ...
ENDPOINTS NEWS14h
With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out
Insilico Medicine reported Phase 2a results for its lead program, saying the study achieved its primary endpoint of safety ...
ENDPOINTS NEWS17h
Ex­clu­sive: For­mer Ama­zon Phar­ma­cy ex­ecs back Me­vo, a start­up bring­ing on­line pre­scrib­ing to Brazil
A startup in Brazil that lets people easily buy medicine online by combining a consumer-friendly experience with prescription ...
ENDPOINTS NEWS6h
Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings
Just hours after the US Federal Reserve announced the first interest rate cut in four years, respiratory biotech Upstream Bio ...
ENDPOINTS NEWS11h
Sen­a­tors tell FDA that ‘greater ac­tion is need­ed’ to use man­u­fac­tur­ing tech in US sup­ply chains
Sens. Mar­co Ru­bio (R-FL) and An­gus King (I-ME) have told the FDA that “con­sid­er­able work” needs to be done to ad­dress ...
ENDPOINTS NEWS1d
No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer
Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...
ENDPOINTS NEWS1d
Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion
A promising new approach that could slow, stop or prevent nerves from dying may get its first test in patients next year.
ENDPOINTS NEWS1d
Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3
One of this weekend’s sleeper data presentations at Europe’s biggest oncology conference puts Pfizer in a leading position in ...